Calendar

Feb
1
Tue
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Feb 1 @ 3:00 pm – 4:00 pm

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

REGISTER FOR ECHO SESSION

Tuesday, February 1, 2022

3:00PM – 4:00PM ET

Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.

PROGRAM OVERVIEW

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

Presenting Faculty:

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

Target Audience

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

REGISTER FOR ECHO SESSION

Feb
3
Thu
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Feb 3 @ 6:00 pm – 7:00 pm

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

REGISTER FOR ECHO SESSION

Thursday, February 3, 2022

6:00PM – 7:00PM ET

Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.

PROGRAM OVERVIEW

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

Presenting Faculty:

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

Target Audience

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

REGISTER FOR ECHO SESSION

Feb
7
Mon
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Feb 7 @ 3:00 pm – 4:00 pm

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

REGISTER FOR ECHO SESSION

Monday, February 7, 2022

3:00PM – 4:00PM ET

Please note this TeleECHO program is 3:00PM Eastern, 2:00PM Central, 1:00PM Mountain and 12:00PM Pacific.

PROGRAM OVERVIEW

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

Presenting Faculty:

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

Target Audience

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

REGISTER FOR ECHO SESSION

Feb
9
Wed
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Feb 9 @ 6:00 pm – 7:00 pm

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

REGISTER FOR ECHO SESSION

Wednesday, February 9, 2022

6:00PM – 7:00PM ET

Please note this TeleECHO program is 6:00PM Eastern, 5:00PM Central, 4:00PM Mountain and 3:00PM Pacific.

PROGRAM OVERVIEW

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

Presenting Faculty:

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

Target Audience

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

REGISTER FOR ECHO SESSION

Feb
12
Sat
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Feb 12 @ 9:00 am – 10:00 am

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

REGISTER FOR ECHO SESSION

Saturday, February 12, 2022

9:00AM – 10:00AM ET

Please note this TeleECHO program is 9:00AM Eastern, 8:00AM Central, 7:00AM Mountain and 6:00AM Pacific.

PROGRAM OVERVIEW

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

Presenting Faculty:

Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

Target Audience

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

REGISTER FOR ECHO SESSION